Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Dr. Abraham S. Kanate

Hematology Oncology | Hematology | Oncology
Honorhealth
7400 E Osborn Rd, 
Scottsdale, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
17 Years of Experience
Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Honorhealth
7400 E Osborn Rd, 
Scottsdale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Abraham Kanate is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Kanate has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kanate is currently accepting new patients.

His clinical research consists of co-authoring 67 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Primary Mediastinal B-Cell Lymphoma (PMBCL).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WV
Hospital Affiliations
Honorhealth Scottsdale Shea Medical Center
Honor Health John C. Lincoln Medical Center
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

HONORHEALTH
7400 E Osborn Rd, Scottsdale, AZ 85251
Other Locations
HONORHEALTH
10460 N 92nd St, Suite 300, Scottsdale, AZ 85258

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Enrollment Status: Recruiting
Publish Date: September 25, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drugs: Panobinostat Capsules, Bortezomib Injection, Dexamethasone Tablets
Study Phase: Phase 2
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drugs: Ixazomib, Ibrutinib
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Pomalidomide, Ixazomib, Dexamethasone
Study Phase: Phase 1/Phase 2
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustin, Bortezomib, Lenalidomide
Study Phase: Phase 2
Unrelated Umbilical Cord Blood (UCB) Transplantation
Unrelated Umbilical Cord Blood (UCB) Transplantation
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Genetic
Study Phase: Not Applicable
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: November 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 10 Less Clinical Trials

67 Total Publications

Corrigendum to 'Clinical Practice Recommendations for Hematopoietic Cell Transplantation.' Transplant Cell Ther. 2024 Sep;30(9):832-843.
Corrigendum to 'Clinical Practice Recommendations for Hematopoietic Cell Transplantation.' Transplant Cell Ther. 2024 Sep;30(9):832-843.
Journal: Transplantation and cellular therapy
Published: June 24, 2025
Similar Doctors
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Nilesh D. Mehta
Oncology | Hematology
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Nilesh D. Mehta
Oncology | Hematology

City Of Hope Medical Group Of Arizona LLC

14200 W Celebrate Life Way, 
Goodyear, AZ 
 (25.5 miles away)
623-207-3000
Languages Spoken:
English, Hindi
See accepted insurances

Nilesh Mehta is an Oncologist and a Hematologist in Goodyear, Arizona. Dr. Mehta is rated as an Advanced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Bone Marrow Aspiration.

Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Navjeet K. Gandhok
Hematology | Oncology
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Navjeet K. Gandhok
Hematology | Oncology

Sage Hematology And Oncology Plc

13943 N 91st Ave, Suite 101, 
Peoria, AZ 
 (20.8 miles away)
623-254-7271
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Navjeet Gandhok is a Hematologist and an Oncologist in Peoria, Arizona. Dr. Gandhok is rated as an Advanced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Colorectal Cancer, Lynch Syndrome, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Gandhok is currently accepting new patients.

Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Ryan S. Robetorye
Hematology
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Ryan S. Robetorye
Hematology

Mayo Clinic Arizona

5779 E Mayo Blvd, Speciality Building, 
Phoenix, AZ 
 (11.9 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances

Ryan Robetorye is a Hematologist in Phoenix, Arizona. Dr. Robetorye is rated as a Distinguished provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Acute Myelomonocytic Leukemia, Chronic B-Cell Leukemia (CBCL), Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kanate's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 19 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile